<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04518293</url>
  </required_header>
  <id_info>
    <org_study_id>GMRx2-HTN-2020-ACT1</org_study_id>
    <nct_id>NCT04518293</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension</brief_title>
  <acronym>GMRx2_ACT</acronym>
  <official_title>Efficacy and Safety of GMRx2 (a Single Pill Combination Containing Telmisartan/Amlodipine/Indapamide) Compared to Dual Combinations for the Treatment of Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>George Medicines PTY Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>George Medicines PTY Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent hypertension guidelines recommend combination therapy as initial treatment for many or&#xD;
      most patients. Several trials suggest triple low-dose combination therapy may be highly&#xD;
      effective in terms of achieving blood pressure control without increasing adverse effects.&#xD;
      This trial is designed to investigate the efficacy and safety of GMRx2 in participants with&#xD;
      high blood pressure compared to dual combinations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TRIAL DRUG:&#xD;
&#xD;
      GMRx2: Single pill combinations of telmisartan/amlodipine/indapamide Dose version 2:&#xD;
      telmisartan 20mg/amlodipine 2.5mg/indapamide 1.25mg Dose version 3: telmisartan&#xD;
      40mg/amlodipine 5 mg/indapamide 2.5mg INDICATION: Hypertension TRIAL DESIGN: International,&#xD;
      multicenter, randomized, double-blind, active controlled, parallel-group.&#xD;
&#xD;
      OBJECTIVES: To investigate the efficacy and safety of GMRx2 compared to dual combinations&#xD;
&#xD;
      INTERVENTION:&#xD;
&#xD;
      Single-Blind Active Run-In Period. Enrolled participants will be asked to discontinue their&#xD;
      current BP-lowering drug(s) and undergo a single-blind active run-in period for 4 weeks with&#xD;
      GMRx2 dose version 2. Participants will be advised to take the capsule once daily in the&#xD;
      morning at the same time (± 2 hours) before home BP measurement is performed.&#xD;
&#xD;
      Double-Blind Treatment Period. Participants still eligible after the run-in period will be&#xD;
      allocated in a double-blind fashion to one of the following 4 randomized groups: GMRx2 dose&#xD;
      version 2, or telmisartan20mg+amlodipine2.5mg, or telmisartan 20mg+indapamide 1.25mg, or&#xD;
      amlodipine2.5mg+indapamide 1.25mg. At week 6 all doses will be doubled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 26, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>International, multicenter, randomized, double-blind, active-controlled, parallel group.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in change in home SBP from baseline to week 12</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in change in clinic seated mean SBP from baseline to Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in change in clinic seated mean SBP from baseline to Week 6</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in change in clinic seated mean DBP from baseline to Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in change in clinic seated mean DBP from baseline to Week 6</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with clinic seated mean SBP &lt;140 and DBP &lt;90 mmHg at Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with clinic seated mean SBP &lt;140 and DBP &lt;90 mmHg at Week 6</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with clinic seated mean SBP &lt;130 and DBP &lt;80 mmHg at Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with clinic seated mean SBP &lt;130 and DBP &lt;80 mmHg at Week 6</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in change in home seated mean SBP from baseline to Week 6</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in change in home seated mean DBP from baseline to Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in change in home seated mean DBP from baseline to Week 6</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in change in trough home seated mean SBP from baseline to week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in change in trough home seated mean SBP from baseline to Week 6</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with home seated mean SBP &lt;135 and DBP &lt;85 mmHg at Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with home seated mean SBP &lt;135 and DBP &lt;85 mmHg at Week 6</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with home seated mean SBP &lt;130 and DBP &lt;80 mmHg at Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with home seated mean SBP &lt;130 and DBP &lt;80 mmHg at Week 6</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety Outcomes</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of participants discontinued trial medication due to AE/SAE from baseline to week 12</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcomes</measure>
    <time_frame>6 weeks</time_frame>
    <description>Percentage of participants discontinued trial medication due to AE/SAE from baseline to Week 6</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcomes</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of participants with an SAE from baseline to Week 12</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcomes</measure>
    <time_frame>6 weeks</time_frame>
    <description>Percentage of participants with SAE from baseline to Week 6</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcomes</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of participants with symptomatic hypotension from baseline to Week 12</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcomes</measure>
    <time_frame>6 weeks</time_frame>
    <description>Percentage of participants with symptomatic hypotension from baseline to Week 6</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcomes</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of participants with serum sodium concentration below 135 mmol/l at Week 12</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcomes</measure>
    <time_frame>6 weeks</time_frame>
    <description>Percentage of participants with serum sodium concentration below 135 mmol/l at Week 6</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcomes</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of participants with serum sodium concentration above 145 mmol/l at Week 12</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcomes</measure>
    <time_frame>6 weeks</time_frame>
    <description>Percentage of participants with serum sodium concentration above 145 mmol/l at Week 6</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcomes</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of participants with serum potassium concentration below 3.5 mmol/l at Week 12</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcomes</measure>
    <time_frame>6 weeks</time_frame>
    <description>Percentage of participants with serum potassium concentration below 3.5 mmol/l at Week 6</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcomes</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of participants with serum potassium concentration above 5.5 mmol/l at Week 12</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcomes</measure>
    <time_frame>6 weeks</time_frame>
    <description>Percentage of participants with serum potassium concentration above 5.5 mmol/l at Week 6</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcomes</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of participants with eGFR drop of over 30% from baseline to Week 12</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcomes</measure>
    <time_frame>6 weeks</time_frame>
    <description>Percentage of participants with eGFR drop of over 30% from baseline to Week 6</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Triple - TAI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dual - TA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telmisartan 20 mg/amlodipine 2.5 mg . At week 6 visit, forced up-titration to telmisartan 40 mg/amlodipine 5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dual - TI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telmisartan 20 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to telmisartan 40 mg/indapamide 2.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dual - AI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amlodipine 2.5 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to amlodipine 5 mg/indapamide 2.5 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg</intervention_name>
    <description>Single pill</description>
    <arm_group_label>Triple - TAI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg</intervention_name>
    <description>Signle pill</description>
    <arm_group_label>Triple - TAI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 20 mg/amlodipine 2.5 mg .</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Dual - TA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan 40 mg/amlodipine 5 mg</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Dual - TA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 20 mg/indapamide 1.25 mg</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Dual - TI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan 40 mg/indapamide 2.5 mg</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Dual - TI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 2.5 mg/indapamide 1.25 mg</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Dual - AI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amlodipine 5 mg/indapamide 2.5 mg</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Dual - AI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        At screening visit&#xD;
&#xD;
          1. Provided signed consent to participate in the trial.&#xD;
&#xD;
          2. Adult of age ≥18 years.&#xD;
&#xD;
          3. Attended automated clinic seated mean SBP (average of last 2 measurements calculated&#xD;
             by the device):&#xD;
&#xD;
        150-179 mmHg on 0 blood pressure (BP)-lowering drugs, or 140-170 mmHg on 1 BP-lowering&#xD;
        drug, or 130-160 mmHg on 2 BP-lowering drugs, or 120-150 mmHg on 3 BP-lowering drugs.&#xD;
&#xD;
        At randomization visit&#xD;
&#xD;
          1. Home seated mean SBP 110-154 mmHg in the week prior to the randomization visit .&#xD;
&#xD;
          2. Adherence of 80-120% to run-in medication.&#xD;
&#xD;
          3. Tolerated run-in medication.&#xD;
&#xD;
          4. Adherence to home BP monitoring schedule: ≥3 days in the week before the randomization&#xD;
             visit and ≥1 day per week during the preceding weeks, , with ≥2 measures in the&#xD;
             specified morning and evening time periods on each day (i.e. accepting measures&#xD;
             outside of the recommended 0600-1000 and 1800-2200 periods as long as they are in the&#xD;
             am or pm, respectively).&#xD;
&#xD;
        At week 12 (for optional open-label extension)&#xD;
&#xD;
          1. Provided signed informed consent.&#xD;
&#xD;
          2. completed randomized treatment and willing to continue GMRx2-based regimen for up to&#xD;
             12 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        At screening visit&#xD;
&#xD;
          1. Receiving 4 or more BP-lowering drugs.&#xD;
&#xD;
          2. receiving any BP lowering drugs for indications other than hypertension e.g. heart&#xD;
             failure&#xD;
&#xD;
          3. Pregnant or had a positive pregnancy test or unwilling to undertake a pregnancy test&#xD;
             during the trial and up to 30 days after the discontinuation of the trial medication&#xD;
             or breastfeeding or of childbearing age and not using an acceptable method of&#xD;
             contraception. Acceptable methods of birth control include hormonal prescription oral&#xD;
             contraceptives, contraceptive injections, contraceptive patch, intrauterine device,&#xD;
             double-barrier method (e.g. condoms, diaphragm, or cervical cap with spermicidal foam,&#xD;
             cream, or gel), or male partner sterilization. Contraception should be used for at&#xD;
             least 1 month before the screening visit and until the end of trial participation.&#xD;
&#xD;
          4. Not suitable for participation in a clinical trial according to local ethical or&#xD;
             regulatory requirements related to severe acute respiratory syndrome coronavirus-2&#xD;
             (SARS-CoV-2).&#xD;
&#xD;
          5. Contraindication, including hypersensitivity (e.g. anaphylaxis or angioedema), to the&#xD;
             active run-in treatment or to any of the trial medication options in the four&#xD;
             randomized groups.&#xD;
&#xD;
          6. Current/history of transient ischemic attack, stroke, or hypertensive encephalopathy.&#xD;
&#xD;
          7. Current/history of acute coronary syndrome, unstable angina, myocardial infarction,&#xD;
             percutaneous transluminal coronary revascularization, or coronary artery bypass graft.&#xD;
&#xD;
          8. Current atrial fibrillation. Patients with a history of paroxysmal atrial fibrillation&#xD;
             are potentially eligible as long as there has been no episode in the last 3 months,&#xD;
             while patient with a history of persistent or permanent atrial fibrillation are not&#xD;
             eligible.&#xD;
&#xD;
          9. Current/history of New York Heart Association class III and IV congestive heart&#xD;
             failure.&#xD;
&#xD;
         10. Current/history of a known secondary cause of hypertension, such as primary&#xD;
             aldosteronism, renal artery stenosis, pheochromocytoma, or Cushing's syndrome.&#xD;
&#xD;
         11. Current/history of substantially uncontrolled diabetes (HbA1c &gt; 11.0%) within last&#xD;
             three months.&#xD;
&#xD;
         12. Current/history of end-stage renal disease or anuria or estimated glomerular&#xD;
             filtration rate (eGFR) &lt;60 ml/min/1.73m2.&#xD;
&#xD;
         13. Electrolyte levels that would be regarded as contraindications for any of the&#xD;
             potential treatment arms e.g. serum sodium &lt;132mmol/l or &gt;148mmol/l serum potassium&#xD;
             &lt;3.1 mmol/l or &gt;5.6 mmol/l.&#xD;
&#xD;
         14. Current/history of aspartate aminotransferase (AST) or alanine aminotransferase (ALT)&#xD;
             &gt;3 times the upper limit of normal range within 6 months.&#xD;
&#xD;
         15. Current concomitant illness or physical impairment or mental condition that in the&#xD;
             judgment of the investigator could interfere with the effective conduct of the trial&#xD;
             or constitutes a significant risk to the participants' well-being.&#xD;
&#xD;
         16. Arm circumference that is too large (&gt;55 cm) or too small (&lt;20 cm) to allow accurate&#xD;
             measurement of BP.&#xD;
&#xD;
         17. Currently taking or might need during the trial, a concomitant treatment which is&#xD;
             known to interact with one or more of the trial medications: digoxin, lithium,&#xD;
             diabetics receiving aliskiren, moderate and strong CYP3A4 inhibitors (e.g. ritonavir,&#xD;
             ketoconazole, diltiazem], simvastatin &gt;20 mg/day, immunosuppressants.&#xD;
&#xD;
         18. Might need treatment with drugs that are prohibited during the trial: other&#xD;
             antihypertensive drugs, endothelin receptor antagonists, neprilysin inhibitors, or&#xD;
             other drugs that may affect BP (see Appendix 5).&#xD;
&#xD;
         19. Current surgical or medical condition that might significantly alter the absorption,&#xD;
             distribution, metabolism, or excretion of trial drugs such as prior major&#xD;
             gastrointestinal tract surgery (e.g. gastrectomy, lap band, or bowel resection) or&#xD;
             acute flare of inflammatory bowel disease within one year.&#xD;
&#xD;
         20. Individuals working &gt;2 nightshifts per week.&#xD;
&#xD;
         21. Participated in any investigative drug or device trial within the previous 30 days.&#xD;
&#xD;
         22. History of alcohol or drug abuse within 12 months.&#xD;
&#xD;
        At randomization visit&#xD;
&#xD;
          1. Unable to adhere to the trial procedures during the run-in treatment period.&#xD;
&#xD;
          2. Any of the following which in the investigator's judgment may compromise the safety of&#xD;
             the participant if randomized to the trial medications:&#xD;
&#xD;
               1. High or low clinic BP levels even in the light of the values for home BP that are&#xD;
                  available for that participant. The exact levels of BP are not specified, since&#xD;
                  there is clinical uncertainty as to the relevance of BP levels which are high or&#xD;
                  low in clinic only; for example, the clinical relevance of 'whitecoat&#xD;
                  hypertension' is uncertain.&#xD;
&#xD;
               2. High or low home diastolic BP (DBP) levels. The exact levels of DBP is not&#xD;
                  specified, reflecting clinical uncertainty of the implications of isolated&#xD;
                  diastolic hypertension. However, home DBP values of &gt;99 mmHg may typically be&#xD;
                  considered as requiring treatment intensification, and such participants would&#xD;
                  not be suitable for randomization.&#xD;
&#xD;
          3. Any abnormal laboratory value which in the judgment of the investigator could&#xD;
             interfere with the effective conduct of the trial or constitutes a significant risk to&#xD;
             the participants' well-being.&#xD;
&#xD;
          4. Fulfilling any of the exclusion criteria mentioned for the screening visit, when&#xD;
             verified again at randomization visit.&#xD;
&#xD;
        At week 12 (for optional open-label extension)&#xD;
&#xD;
        1. contraindication to open-label GMRx2-ased BP-lowering treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Rodgers, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erin Corstanje</last_name>
    <phone>M +44 (0)7879192633</phone>
    <email>ecorstanje@george-medicines.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Suzanne Milne</last_name>
    <phone>+19013900306</phone>
    <email>gmrx2gpm@georgeclinical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Precision Research Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernesto Perez</last_name>
      <phone>813-513-2365</phone>
      <email>efpd12@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Venkata Bireddy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 15, 2020</study_first_submitted>
  <study_first_submitted_qc>August 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Indapamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

